BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) - Equities researchers at HC Wainwright dropped their Q2 2025 EPS estimates for BioHarvest Sciences in a research note issued on Monday, May 19th. HC Wainwright analyst A. Dayal now forecasts that the company will earn ($0.11) per share for the quarter, down from their previous estimate of ($0.10). HC Wainwright currently has a "Buy" rating and a $14.00 target price on the stock. The consensus estimate for BioHarvest Sciences' current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BioHarvest Sciences' Q3 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.30) EPS.
Separately, Craig Hallum began coverage on shares of BioHarvest Sciences in a research note on Monday, May 5th. They set a "buy" rating and a $15.00 target price on the stock.
Check Out Our Latest Research Report on BHST
BioHarvest Sciences Trading Up 2.3%
Shares of NASDAQ:BHST traded up $0.14 during midday trading on Wednesday, reaching $6.29. 10,027 shares of the company's stock traded hands, compared to its average volume of 17,352. BioHarvest Sciences has a one year low of $6.12 and a one year high of $7.38. The company has a market capitalization of $103.31 million, a P/E ratio of -5.04 and a beta of 0.80. The stock's 50 day moving average price is $6.16.
BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.02. The business had revenue of $7.64 million for the quarter, compared to analysts' expectations of $8.93 million.
Institutional Trading of BioHarvest Sciences
Large investors have recently modified their holdings of the company. TD Waterhouse Canada Inc. purchased a new position in shares of BioHarvest Sciences in the fourth quarter worth approximately $69,000. True North Advisors LLC lifted its position in shares of BioHarvest Sciences by 7.6% during the 1st quarter. True North Advisors LLC now owns 44,391 shares of the company's stock valued at $275,000 after buying an additional 3,120 shares in the last quarter. Finally, Magnus Financial Group LLC lifted its holdings in BioHarvest Sciences by 105.0% during the first quarter. Magnus Financial Group LLC now owns 71,733 shares of the company's stock valued at $444,000 after purchasing an additional 36,733 shares in the last quarter.
BioHarvest Sciences Company Profile
(
Get Free Report)
BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.
Recommended Stories
Before you consider BioHarvest Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioHarvest Sciences wasn't on the list.
While BioHarvest Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
